This JACC: Heart Failure position statement proposes a framework for defining clinically meaningful within-patient change (CMWPC) across the full range of HF trial endpoints—hospitalizations, imaging (echo/CMR), hemodynamics, biomarkers, functional tests (CPET, 6MWD), and patient-reported outcomes (PROs)—integrating measurement variability, prognostic data, and patient-anchored evidence.
Key proposed thresholds include: **KCCQ**: ≥5 points = small but clinically important change; ≥10–15 = moderate–large; **NT-proBNP/BNP**: ≥30% rise or fall; **LVEF (echo)**: ±5% (2D), ±3% (3D); **LVESV (CMR)**: ≥7 mL; **peak VO₂**: ~6% change; **6MWD**: 14–15 m (iron-deficiency HFrEF trials); **PADP**: ≥2 mm Hg change linked to 14.7–26.7% mortality difference; **clinical events**: ARR of ~2–5% over 12–24 months (NNT ~20–50) aligns with strong guideline endorsement, and a ≥15–20% RRR is conventional but must be contextualized by baseline risk.
- Most proposed cutpoints are provisional, lacking anchor-based validation linking physiological changes to patient-perceived benefit or hard outcomes. - Many thresholds derive from group-mean analyses rather than true intraindividual change data. - Measurement variability (imaging, hemodynamics) is substantial and context-dependent, limiting cross-trial comparisons.
When discussing HF trial results with patients, convert mean group differences into NNT and distributions of responders—a 2.5-point mean KCCQ difference between arms translates to an NNT of ~17 for one patient to feel meaningfully better. Use KCCQ thresholds (≥5 points = meaningful change) and a ≥30% natriuretic peptide shift as the best-validated benchmarks when interpreting individual patient response.
Explore related topics
